Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 outpatients meta-analysis

Chaccour
  NCT04390022		 RCTivermectinplaceboCOVID 19 outpatients, COVID-19 mild to moderatelow
12/12 inconclusive
  • inconclusive 8 % decrease in viral clearance ,viral clearance by day 7 (PE) with a high degree of certainty due to low risk of bias

COVID 19 hospitalized meta-analysis

Gonzalez (IVER)
  NCT04391127		 RCTivermectinplaceboCOVID 19 hospitalizedsome concern
36/37 inconclusive

    COVID-19 mild to moderate meta-analysis

    Kirti
          CTRI/2020/08/027225    		 RCTivermectinplaceboCOVID-19 mild to moderatesome concern
    		57/58 inconclusive
    • inconclusive 20 % decrease in viral clearance by day 7 (PE) with a moderate degree of certainty due to some concern in risk of bias
    RIVET-COV (Mohan) (12mg and 24mg)
          CTRI/2020/06/026001    		 RCTivermectinplaceboCOVID-19 mild to moderatehigh
    		104/52 inconclusive
    • inconclusive 10 % increase in viral clearance ,viral clearance by day 7 (PE) but with a low degree of certainty due to high risk of bias
    Ahmed RCTivermectinplaceboCOVID-19 mild to moderatehigh
    		48/24 suggested
    • suggested 3.1-fold increase in viral clearance (time to event analysis only),viral clearance by day 14 (PE) but with a low degree of certainty due to high risk of bias
    Paradoxically comparison of day 7 and 14 virological clearance between ivermectin doxycycline group vs placebo was not statistically significant (HR 2.3[0.6-9.0] and 1.7[0.8-4.0])
    1 study excluded by filtering options (0 RCT / 1 OBS)

    PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
    Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

     

    - About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons